SyntheX utilizes its ToR _FLEx_ platform to engineer cells for drug discovery, enabling the identification of selective drugs that target previously inaccessible proteins. This approach addresses the limitation of existing drug discovery technologies, which can only access 15% of the proteome, by exploiting novel mechanisms of action to modulate protein interactions and levels.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing drug discovery technologies can only access a small fraction of the human proteome, limiting the development of new treatments for many diseases. Traditional methods often struggle to replicate the complexity of a cell and capture proteins in their native environments, hindering the identification of effective drug candidates.
Solution
SyntheX utilizes its ToR _FLEx_ platform to engineer cells for drug discovery, enabling the identification of selective drugs that target previously inaccessible proteins. The platform exploits novel mechanisms of action to modulate protein interactions and levels, expanding the range of druggable targets. By engineering cells to carry out drug discovery, SyntheX aims to unlock novel pharmacology and mechanisms of action, leading to faster, better, and cheaper drug discovery. This approach allows for target-centric, cell-based functional selection, addressing the limitations of traditional in-vitro binding assays and computational modeling.
Target Audience
The primary audience includes pharmaceutical companies and research institutions seeking to expand their drug discovery efforts to previously inaccessible protein targets.
Features
- ToR _FLEx_ platform for engineering cells to carry out drug discovery.
- Target-centric cell-based functional selection.
- Identification of selective drugs that modulate challenging protein targets.
- Exploitation of novel mechanisms of action to modulate protein levels or their interactions.